# Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

> **NCT02476955** · PHASE1 · TERMINATED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 41 (actual)

## Conditions studied

- Solid Tumors
- Ovarian Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** ARQ 092 + carboplatin + paclitaxel (Closed)
- **DRUG:** ARQ 092 + paclitaxel (Closed)
- **DRUG:** ARQ 092 + anastrozole

## Key facts

- **NCT ID:** NCT02476955
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-09
- **Primary completion:** 2019-05-07
- **Final completion:** 2019-05-07
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02476955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02476955, "Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02476955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*